BLMN
Bloomin' Brands, Inc.
BLMN has the edge over F overall, supported by stronger valuation and stronger fundamentals.
F
Ford Motor Company
F has lower modeled downside risk, despite its lower overall score.
BLMN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
BLMN's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
F Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
F's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
BLMN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.3x | $10.12 | — |
| Cheap | 9.8x | $8.08 | -20% |
| Current | 12x | $10.12 | — |
| Fair | 22x | $18.19 | +80% |
| Expensive | 34x | $27.95 | +176% |
Historical ranges are pointers, not guarantees.
BLMN's PE is in its cheap range at 12x. If earnings grow as analysts expect, today's price would be 9.3x next year's earnings.
F PE Valuation
F has no meaningful PE right now: it lost money over the past year.
BLMN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect BLMN's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
F Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
F has the edge over BLMN on the outlook, with more favorable profitability expectations.
BLMN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.09 | +33% |
| Q3 2026 | $0.82 | +$1.49 |
| Q2 2026 | $0.31 | +$0.36 |
| Q1 2026 | $0.25 | +$0.28 |
| Q4 2025 | $0.10 | +$1.59 |
| Q3 2025 | -$0.67 | -$0.59 |
| Q2 2025 | -$0.05 | -117% |
| Q1 2025 | -$0.03 | -104% |
| Q4 2024 | -$1.49 | -158% |
BLMN has the edge over F on earnings quality, reporting a profit while its opponent remains loss making.
F Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.78 | — |
| Q3 2026 | -$1.97 | -270% |
| Q2 2026 | -$1.87 | -340% |
| Q1 2026 | -$1.55 | -224% |
| Q4 2025 | -$2.06 | -241% |
| Q3 2025 | $1.16 | +32% |
| Q2 2025 | $0.78 | -19% |
| Q1 2025 | $1.25 | +29% |
| Q4 2024 | $1.46 | +35% |
F has swung to a loss: it lost $1.97 per share over the past year, after a profit the year before.
BLMN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $944.3M | +1.7% |
| Q2 2026 | $1B | +1.3% |
| Q1 2026 | $1.1B | +1% |
| Q4 2025 | $975.2M | +0.3% |
| Q3 2025 | $928.8M | -11% |
| Q2 2025 | $1B | -10% |
| Q1 2025 | $1B | -12% |
| Q4 2024 | $972M | -19% |
BLMN's revenue fell from its 2023 peak and has held roughly level since: $944M last quarter, up 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2% | +5.9 points |
| Q2 2026 | 3.8% | +0.8 points |
| Q1 2026 | 5.6% | +0.1 points |
| Q4 2025 | -1.4% | -3 points |
| Q3 2025 | -3.9% | -5.6 points |
| Q2 2025 | 3% | -1.2 points |
| Q1 2025 | 5.5% | -1 points |
| Q4 2024 | 1.7% | -3.1 points |
BLMN's operating margin was 2% last quarter, up 5.9 points from the same quarter a year ago.
F Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $49.5B | -2% |
| Q2 2026 | $48.3B | -3.8% |
| Q1 2026 | $43.3B | +6.4% |
| Q4 2025 | $45.9B | -4.8% |
| Q3 2025 | $50.5B | +9.4% |
| Q2 2025 | $50.2B | +5% |
| Q1 2025 | $40.7B | -5% |
| Q4 2024 | $48.2B | +4.9% |
F has the edge over BLMN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.9% | -0.1 points |
| Q2 2026 | 1.3% | +0.3 points |
| Q1 2026 | 5.4% | +4.6 points |
| Q4 2025 | -25% | -28 points |
| Q3 2025 | 3.1% | +1.2 points |
| Q2 2025 | 1% | -2.9 points |
| Q1 2025 | 0.8% | -2.1 points |
| Q4 2024 | 2.5% | +3.1 points |
F has the edge over BLMN on profitability, with a higher operating margin.
BLMN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.2M | -$33.5M |
| Q2 2026 | $46.9M | +321% |
| Q1 2026 | $50.1M | +81% |
| Q4 2025 | $63.7M | -35% |
| Q3 2025 | -$5.7M | +$69.2M |
| Q2 2025 | $11.1M | +$35.4M |
| Q1 2025 | $27.7M | +211% |
| Q4 2024 | $97.7M | +58% |
BLMN has the edge over F on cash flow, with more consistent year-over-year improvement.
F Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.1B | -40% |
| Q2 2026 | $2B | -54% |
| Q1 2026 | -$1.1B | -157% |
| Q4 2025 | $1.1B | +108% |
| Q3 2025 | $5.3B | +50% |
| Q2 2025 | $4.2B | +24% |
| Q1 2025 | $1.9B | +$2.6B |
| Q4 2024 | $530M | +169% |
F still generates free cash flow, though less than at its 2020 peak: $5.1B over the past year.
BLMN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -587K shares |
| 1 year | +0.6% | +543K shares |
| 3 years | -13% | -12.9M shares |
| 5 years | -21% | -22.1M shares |
| Available history | -4.6% | -4.1M shares |
BLMN has the edge over F on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $18.2M |
| Q2 2024 | $14.6M |
| Q1 2024 | $232.9M |
F Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +89M shares |
| 1 year | +0.7% | +28M shares |
| 3 years | +0.6% | +26M shares |
| 5 years | +1% | +40M shares |
| Available history | +1.8% | +72M shares |
F has 4.1B diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $311M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $150M |
F spent $311M buying back its own shares over the past year, up 107% from the year before.
BLMN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.8x | Moderate |
| Q1 2026 | 3.1x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q2 2025 | 3.0x | Elevated |
| Q1 2025 | 2.8x | Moderate |
| Q4 2024 | 2.9x | Moderate |
BLMN's net debt is about 2.4 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
F Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.5x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -3.4x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
F has the edge over BLMN on leverage, with a lower net debt burden relative to earnings.
BLMN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.2 | Neutral |
| Stochastic | 53.6 | Neutral |
BLMN's weekly RSI is 56 (neutral) and its Stochastic is 54 (neutral).
F Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 19.6 | Oversold |
F's weekly RSI is 41 (neutral) and its Stochastic is 20 (oversold).
BLMN PE vs Consumer Cyclical Sector
| Metric | BLMN | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 18x | 32% below |
| PE % | 31 | 47 | 16 pts below |
BLMN is trading at 12x earnings, a 32% discount to the Consumer Cyclical sector's median of 18x.
F PE vs Consumer Cyclical Sector
| Metric | F | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
F has no meaningful PE right now: it lost money over the past year.
BLMN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.32 | 8.6% above |
| 20 week MA | $9.35 | 8.2% above |
| 50 week MA | $7.86 | 29% above |
| 100 week MA | $8.25 | 23% above |
| 200 week MA | $15.7 | 36% below |
BLMN has the edge over F on trend strength, trading above more of its moving averages.
F Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.2 | 2.5% below |
| 20 week MA | $13.3 | 11% below |
| 50 week MA | $13.4 | 11% below |
| 100 week MA | $12.1 | 2% below |
| 200 week MA | $12.1 | 1.4% below |
F is in a downtrend: it's below all five of its weekly moving averages, and 1.4% below its 200-week average.
BLMN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.7 | $19.0 | -13% |
| 2021 | $19.0 | $21.0 | +11% |
| 2022 | $21.0 | $21.0 | 0% |
| 2023 | $21.0 | $28.2 | +34% |
| 2024 | $28.2 | $12.3 | -56% |
| 2025 | $12.3 | $6.79 | -45% |
| 2026 YTD | $6.79 | $10.1 | +49% |
BLMN has the edge over F on returns for 2026, with the stronger performance.
F Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.36 | $8.86 | -5.3% |
| 2021 | $8.86 | $20.3 | +129% |
| 2022 | $20.3 | $11.4 | -44% |
| 2023 | $11.4 | $12.2 | +7.3% |
| 2024 | $12.2 | $10.0 | -18% |
| 2025 | $10.0 | $13.3 | +33% |
| 2026 YTD | $13.3 | $11.9 | -11% |
F's yearly returns have swung widely, from +129% in 2021 to −44% in 2022. It's down 11% so far in 2026.